-
2
-
-
78650985963
-
Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era
-
P. Perez-Galan, M. Dreyling, and A. Wiestner Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Blood 117 2011 26 38
-
(2011)
Blood
, vol.117
, pp. 26-38
-
-
Perez-Galan, P.1
Dreyling, M.2
Wiestner, A.3
-
3
-
-
27244434794
-
Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways
-
DOI 10.1200/JCO.2005.05.019
-
V. Fernandez, E. Hartmann, and G. Ott Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways J Clin Oncol 23 2005 6364 6369 (Pubitemid 46218848)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.26
, pp. 6364-6369
-
-
Fernandez, V.1
Hartmann, E.2
Ott, G.3
Campo, E.4
Rosenwald, A.5
-
4
-
-
0038299000
-
Sirolimus: Its discovery, biological properties, and mechanism of action
-
DOI 10.1016/S0041-1345(03)00211-2
-
S.N. Sehgal Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 35 2003 7S 14S (Pubitemid 36547910)
-
(2003)
Transplantation Proceedings
, vol.35
, Issue.SUPPL. 3
-
-
Sehgal, S.N.1
-
5
-
-
34347220473
-
Defining the Role of mTOR in Cancer
-
DOI 10.1016/j.ccr.2007.05.008, PII S1535610807001511
-
D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22 (Pubitemid 47001784)
-
(2007)
Cancer Cell
, vol.12
, Issue.1
, pp. 9-22
-
-
Guertin, D.A.1
Sabatini, D.M.2
-
6
-
-
78650510609
-
MTOR: From growth signal integration to cancer, diabetes and ageing
-
Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol; 12: 21-35.
-
Nat Rev Mol Cell Biol
, vol.12
, pp. 21-35
-
-
Zoncu, R.1
Efeyan, A.2
Sabatini, D.M.3
-
7
-
-
13844312400
-
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
-
DOI 10.1126/science.1106148
-
D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101 (Pubitemid 40262113)
-
(2005)
Science
, vol.307
, Issue.5712
, pp. 1098-1101
-
-
Sarbassov, D.D.1
Guertin, D.A.2
Ali, S.M.3
Sabatini, D.M.4
-
8
-
-
83255188843
-
Regulation, role, and targeting of akt in cancer
-
Davies MA. Regulation, role, and targeting of akt in cancer. J Clin Oncol; 29: 4715-4717.
-
J Clin Oncol
, vol.29
, pp. 4715-4717
-
-
Davies, M.A.1
-
9
-
-
3342895823
-
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
-
DOI 10.1016/j.cub.2004.06.054, PII S0960982204004713
-
D.D. Sarbassov, S.M. Ali, and D.H. Kim Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 2004 1296 1302 (Pubitemid 38991819)
-
(2004)
Current Biology
, vol.14
, Issue.14
, pp. 1296-1302
-
-
Dos D. Sarbassov1
Ali, S.M.2
Kim, D.-H.3
Guertin, D.A.4
Latek, R.R.5
Erdjument-Bromage, H.6
Tempst, P.7
Sabatini, D.M.8
-
10
-
-
67651210833
-
Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth
-
H.A. Acosta-Jaquez, J.A. Keller, and K.G. Foster Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth Mol Cell Biol 29 2009 4308 4324
-
(2009)
Mol Cell Biol
, vol.29
, pp. 4308-4324
-
-
Acosta-Jaquez, H.A.1
Keller, J.A.2
Foster, K.G.3
-
11
-
-
84055178474
-
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
-
B. Magnuson, B. Ekim, and D.C. Fingar Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks Biochem J 441 2012 1 21
-
(2012)
Biochem J
, vol.441
, pp. 1-21
-
-
Magnuson, B.1
Ekim, B.2
Fingar, D.C.3
-
12
-
-
33646917622
-
Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor
-
M. Rivera, J.I. Kreisberg, and M.M. Mita Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor JCO 23 2005 3033
-
(2005)
JCO
, vol.23
, pp. 3033
-
-
Rivera, M.1
Kreisberg, J.I.2
Mita, M.M.3
-
13
-
-
23944481410
-
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
-
DOI 10.1200/JCO.2005.13.466
-
T.E. Witzig, S.M. Geyer, and I. Ghobrial Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 2005 5347 5356 (Pubitemid 46206988)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.23
, pp. 5347-5356
-
-
Witzig, T.E.1
Geyer, S.M.2
Ghobrial, I.3
Inwards, D.J.4
Fonseca, R.5
Kurtin, P.6
Ansell, S.M.7
Luyun, R.8
Flynn, P.J.9
Morton, R.F.10
Dakhil, S.R.11
Gross, H.12
Kaufmann, S.H.13
-
14
-
-
77649286736
-
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E
-
A.C. Hsieh, M. Costa, and O. Zollo Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E Cancer Cell 17 2010 249 261
-
(2010)
Cancer Cell
, vol.17
, pp. 249-261
-
-
Hsieh, A.C.1
Costa, M.2
Zollo, O.3
-
15
-
-
13444259647
-
Regulation of cap-dependent translation by eIF4E inhibitory proteins
-
DOI 10.1038/nature03205
-
J.D. Richter, and N. Sonenberg Regulation of cap-dependent translation by eIF4E inhibitory proteins Nature 433 2005 477 480 (Pubitemid 40204297)
-
(2005)
Nature
, vol.433
, Issue.7025
, pp. 477-480
-
-
Richter, J.D.1
Sonenberg, N.2
-
16
-
-
1642586272
-
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
-
DOI 10.1038/nature02369
-
H.G. Wendel, E. De Stanchina, and J.S. Fridman Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 2004 332 337 (Pubitemid 38418805)
-
(2004)
Nature
, vol.428
, Issue.6980
, pp. 332-337
-
-
Wendel, H.-G.1
De Stanchina, E.2
Fridman, J.S.3
Malina, A.4
Ray, S.5
Kogan, S.6
Cordon-Cardo, C.7
Pelletier, J.8
Lowe, S.W.9
-
17
-
-
70350114434
-
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine
-
K.V. Inamdar, J.E. Romaguera, and E. Drakos Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine Cancer 115 2009 4727 4736
-
(2009)
Cancer
, vol.115
, pp. 4727-4736
-
-
Inamdar, K.V.1
Romaguera, J.E.2
Drakos, E.3
-
18
-
-
30044432434
-
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
-
DOI 10.1038/nm1337
-
G.V. Thomas, C. Tran, and I.K. Mellinghoff Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 2006 122 127 (Pubitemid 43050086)
-
(2006)
Nature Medicine
, vol.12
, Issue.1
, pp. 122-127
-
-
Thomas, G.V.1
Tran, C.2
Mellinghoff, I.K.3
Welsbie, D.S.4
Chan, E.5
Fueger, B.6
Czernin, J.7
Sawyers, C.L.8
-
19
-
-
77953932867
-
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
-
A.P. Bhatt, P.M. Bhende, and S.H. Sin Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 115 2010 4455 4463
-
(2010)
Blood
, vol.115
, pp. 4455-4463
-
-
Bhatt, A.P.1
Bhende, P.M.2
Sin, S.H.3
-
20
-
-
61349141302
-
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2
-
M.E. Feldman, B. Apsel, and A. Uotila Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol 7 2009 e38
-
(2009)
PLoS Biol
, vol.7
, pp. 38
-
-
Feldman, M.E.1
Apsel, B.2
Uotila, A.3
-
21
-
-
0032968603
-
Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas
-
DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9
-
M.P. Butler, S.I. Wang, and R.S. Chaganti Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas Genes Chromosomes Cancer 24 1999 322 327 (Pubitemid 29115870)
-
(1999)
Genes Chromosomes and Cancer
, vol.24
, Issue.4
, pp. 322-327
-
-
Butler, M.P.1
Wang, S.I.2
Chaganti, R.S.K.3
Parsons, R.4
Dalla-Favera, R.5
-
22
-
-
33747846726
-
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
-
DOI 10.1182/blood-2006-04-015586
-
M. Rudelius, S. Pittaluga, and S. Nishizuka Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma Blood 108 2006 1668 1676 (Pubitemid 44316136)
-
(2006)
Blood
, vol.108
, Issue.5
, pp. 1668-1676
-
-
Rudelius, M.1
Pittaluga, S.2
Nishizuka, S.3
Pham, T.H.-T.4
Fend, F.5
Jaffe, E.S.6
Quintanilla-Martinez, L.7
Raffeld, M.8
-
23
-
-
33748128925
-
Inhibition of Akt/mTOR signalling pathway induces cell cycle arrest and apoptosis in mantle cell lymphoma
-
[abstract 2415]
-
E. Peponi, e Drakos, and G. Reyes Inhibition of Akt/mTOR signalling pathway induces cell cycle arrest and apoptosis in mantle cell lymphoma Blood 106 2005 [abstract 2415]
-
(2005)
Blood
, vol.106
-
-
Peponi, E.1
Drakos, E.2
Reyes, G.3
-
24
-
-
0013224058
-
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
-
DOI 10.1016/S1535-6108(03)00028-X
-
A. Rosenwald, G. Wright, and A. Wiestner The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Cancer Cell 3 2003 185 197 (Pubitemid 37443390)
-
(2003)
Cancer Cell
, vol.3
, Issue.2
, pp. 185-197
-
-
Rosenwald, A.1
Wright, G.2
Wiestner, A.3
Chan, W.C.4
Connors, J.M.5
Campo, E.6
Gascoyne, R.D.7
Grogan, T.M.8
Muller-Hermelink, H.K.9
Smeland, E.B.10
Chiorazzi, M.11
Giltnane, J.M.12
Hurt, E.M.13
Zhao, H.14
Averett, L.15
Henrickson, S.16
Yang, L.17
Powell, J.18
Wilson, W.H.19
Jaffe, E.S.20
Simon, R.21
Klausner, R.D.22
Montserrat, E.23
Bosch, F.24
Greiner, T.C.25
Weisenburger, D.D.26
Sanger, W.G.27
Dave, B.J.28
Lynch, J.C.29
Vose, J.30
Armitage, J.O.31
Fisher, R.I.32
Miller, T.P.33
LeBlanc, M.34
Ott, G.35
Kvaloy, S.36
Holte, H.37
Delabie, J.38
Staudt, L.M.39
more..
-
25
-
-
24944592507
-
Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFβ signalling pathways
-
DOI 10.1111/j.1365-2141.2005.05630.x
-
E.G. Rizzatti, R.P. Falcao, and R.A. Panepucci Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways Br J Haematol 130 2005 516 526 (Pubitemid 43899754)
-
(2005)
British Journal of Haematology
, vol.130
, Issue.4
, pp. 516-526
-
-
Rizzatti, E.G.1
Falcao, R.P.2
Panepucci, R.A.3
Proto-Siqueira, R.4
Anselmo-Lima, W.T.5
Okamoto, O.K.6
Zago, M.A.7
-
26
-
-
10744226486
-
The Molecular Signature of Mantle Cell Lymphoma Reveals Multiple Signals Favoring Cell Survival
-
N. Martinez, F.I. Camacho, and P. Algara The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival Cancer Res 63 2003 8226 8232 (Pubitemid 37549472)
-
(2003)
Cancer Research
, vol.63
, Issue.23
, pp. 8226-8232
-
-
Martinez, N.1
Camacho, F.I.2
Algara, P.3
Rodriguez, A.4
Dopazo, A.5
Ruiz-Ballesteros, E.6
Martin, P.7
Martinez-Climent, J.A.8
Garcia-Conde, J.9
Menarguez, J.10
Solano, F.11
Mollejo, M.12
Piris, M.A.13
-
27
-
-
32044445067
-
TORgeting oncogene addiction for cancer therapy
-
DOI 10.1016/j.ccr.2006.01.021, PII S1535610806000316
-
A.Y. Choo, and J. Blenis TORgeting oncogene addiction for cancer therapy Cancer Cell. 9 2006 77 79 (Pubitemid 43202658)
-
(2006)
Cancer Cell
, vol.9
, Issue.2
, pp. 77-79
-
-
Choo, A.Y.1
Blenis, J.2
-
28
-
-
34948830177
-
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
-
DOI 10.1182/blood-2005-11-026344
-
N. Kawamata, J. Chen, and H.P. Koeffler Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells Blood 110 2007 2667 2673 (Pubitemid 47523191)
-
(2007)
Blood
, vol.110
, Issue.7
, pp. 2667-2673
-
-
Kawamata, N.1
Chen, J.2
Koeffler, H.P.3
-
29
-
-
51849147986
-
GSK-3beta inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma
-
J. Dal Col, and R. Dolcetti GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma Cell Cycle 7 2008 2813 2816
-
(2008)
Cell Cycle
, vol.7
, pp. 2813-2816
-
-
Dal Col, J.1
Dolcetti, R.2
-
30
-
-
1642535431
-
AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression
-
DOI 10.1074/jbc.M309999200
-
J.F. Gera, I.K. Mellinghoff, and Y. Shi AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression J Biol Chem 279 2004 2737 2746 (Pubitemid 38114263)
-
(2004)
Journal of Biological Chemistry
, vol.279
, Issue.4
, pp. 2737-2746
-
-
Gera, J.F.1
Mellinghoff, I.K.2
Shi, Y.3
Rettig, M.B.4
Tran, C.5
Hsu, J.-H.6
Sawyers, C.L.7
Lichtenstein, A.K.8
-
31
-
-
46749155539
-
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
-
J. Dal Col, P. Zancai, and L. Terrin Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma Blood 111 2008 5142 5151
-
(2008)
Blood
, vol.111
, pp. 5142-5151
-
-
Dal Col, J.1
Zancai, P.2
Terrin, L.3
-
32
-
-
34248653084
-
Antiproliferative activity of RAD001 as a single-agent and combined with other agents in mantle cell lymphoma
-
[2197abstract]
-
T. Haritunians, A. Mori, and J. O'Kelly Antiproliferative activity of RAD001 as a single-agent and combined with other agents in mantle cell lymphoma Am Assoc Can Res 2006 [2197abstract]
-
(2006)
Am Assoc Can Res
-
-
Haritunians, T.1
Mori, A.2
O'Kelly, J.3
-
33
-
-
34248647440
-
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma
-
DOI 10.2353/ajpath.2006.051078
-
E. Peponi, E. Drakos, and G. Reyes Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma Am J Pathol 169 2006 2171 2180 (Pubitemid 351181976)
-
(2006)
American Journal of Pathology
, vol.169
, Issue.6
, pp. 2171-2180
-
-
Peponi, E.1
Drakos, E.2
Reyes, G.3
Leventaki, V.4
Rassidakis, G.Z.5
Medeiros, L.J.6
-
34
-
-
27144455334
-
Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells
-
S. Hipp, I. Ringshausen, and M. Oelsner Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells Haematologica 90 2005 1433 1434 (Pubitemid 41503659)
-
(2005)
Haematologica
, vol.90
, Issue.10
, pp. 1433-1434
-
-
Hipp, S.1
Ringshausen, I.2
Oelsner, M.3
Bogner, C.4
Peschel, C.5
Decker, T.6
-
35
-
-
33846794896
-
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
-
DOI 10.1172/JCI28833
-
R.K. Amaravadi, D. Yu, and J.J. Lum Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma J Clin Invest 117 2007 326 336 (Pubitemid 46203961)
-
(2007)
Journal of Clinical Investigation
, vol.117
, Issue.2
, pp. 326-336
-
-
Amaravadi, R.K.1
Yu, D.2
Lum, J.J.3
Bui, T.4
Christophorou, M.A.5
Evan, G.I.6
Thomas-Tikhonenko, A.7
Thompson, C.B.8
-
36
-
-
84863393353
-
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
-
M. Gupta, A.E. Wahner Hendrickson, and S.S. Yun Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies Blood 119 2012 476 487
-
(2012)
Blood
, vol.119
, pp. 476-487
-
-
Gupta, M.1
Wahner Hendrickson, A.E.2
Yun, S.S.3
-
37
-
-
76749118059
-
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
-
Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res; 70: 1408-1418.
-
Cancer Res
, vol.70
, pp. 1408-1418
-
-
Fernandez, V.1
Salamero, O.2
Espinet, B.3
-
38
-
-
2942735384
-
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
-
DOI 10.1200/JCO.2004.08.116
-
E. Raymond, J. Alexandre, and S. Faivre Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2004 2336 2347 (Pubitemid 41115390)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.12
, pp. 2336-2347
-
-
Raymond, E.1
Alexandre, J.2
Faivre, S.3
Vera, K.4
Materman, E.5
Boni, J.6
Leister, C.7
Korth-Bradley, J.8
Hanauske, A.9
Armand, J.-P.10
-
39
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
DOI 10.1056/NEJMoa066838
-
G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.22
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
Staroslawska, E.7
Sosman, J.8
McDermott, D.9
Bodrogi, I.10
Kovacevic, Z.11
Lesovoy, V.12
Schmidt-Wolf, I.G.H.13
Barbarash, O.14
Gokmen, E.15
O'Toole, T.16
Lustgarten, S.17
Moore, L.18
Motzer, R.J.19
-
40
-
-
68949102180
-
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
-
G. Hess, R. Herbrecht, and J. Romaguera Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 2009 3822 3829
-
(2009)
J Clin Oncol
, vol.27
, pp. 3822-3829
-
-
Hess, G.1
Herbrecht, R.2
Romaguera, J.3
-
41
-
-
84862231092
-
Effect of prognostic risk classification on temsirolimus efficacy and safety outcomes in patients with relapsed/refractory mantle cell lymphoma
-
G. Hess, L. Kang, and P.J. Moran Effect of prognostic risk classification on temsirolimus efficacy and safety outcomes in patients with relapsed/refractory mantle cell lymphoma Blood 2011 118
-
(2011)
Blood
, pp. 118
-
-
Hess, G.1
Kang, L.2
Moran, P.J.3
-
42
-
-
79958840413
-
PILLAR-1: Preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib
-
O. O'Connor, L. Popplewell, and J. Winter PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib Blood 2010 116
-
(2010)
Blood
, pp. 116
-
-
O'Connor, O.1
Popplewell, L.2
Winter, J.3
-
43
-
-
79960510811
-
A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
-
C. Renner, P.L. Zinzani, and R. Gressin A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma Blood 2010 116
-
(2010)
Blood
, pp. 116
-
-
Renner, C.1
Zinzani, P.L.2
Gressin, R.3
-
44
-
-
79953182631
-
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study
-
S.M. Ansell, H. Tang, and P.J. Kurtin Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study Lancet Oncol 12 2011 361 368
-
(2011)
Lancet Oncol
, vol.12
, pp. 361-368
-
-
Ansell, S.M.1
Tang, H.2
Kurtin, P.J.3
-
45
-
-
20044381673
-
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss group for clinical cancer research (SAKK)
-
DOI 10.1200/JCO.2005.04.164
-
M. Ghielmini, S.F. Schmitz, and S. Cogliatti Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK) J Clin Oncol 23 2005 705 711 (Pubitemid 46224169)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 705-711
-
-
Ghielmini, M.1
Schmitz, S.-F.H.2
Cogliatti, S.3
Bertoni, F.4
Waltzer, U.5
Fey, M.F.6
Betticher, D.C.7
Schefer, H.8
Pichert, G.9
Stahel, R.10
Ketterer, N.11
Bargetzi, M.12
Cerny, T.13
-
46
-
-
84867334720
-
Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: Report on an ongoing phase I/II trial
-
G. Hess, U. Keller, and J. Atta Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I/II trial Blood 2011 118
-
(2011)
Blood
, pp. 118
-
-
Hess, G.1
Keller, U.2
Atta, J.3
-
47
-
-
84880890111
-
CAL-101 (GS-1101), a specific inhibitor of phosphatidylinositol-3-Kinase- Delta (PI3K), disrupts signals from the microenvironment, induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell lymphoma (MCL)
-
S.A. Meadows, A. Kashishian, and D. Johnson CAL-101 (GS-1101), a specific inhibitor of phosphatidylinositol-3-Kinase-Delta (PI3K), disrupts signals from the microenvironment, induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell lymphoma (MCL) Blood 2011 118
-
(2011)
Blood
, pp. 118
-
-
Meadows, S.A.1
Kashishian, A.2
Johnson, D.3
-
48
-
-
84862193169
-
Phase i trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies
-
S. Kumar, J.R. Mikhael, and B. Laplant Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies Blood 2011 118
-
(2011)
Blood
, pp. 118
-
-
Kumar, S.1
Mikhael, J.R.2
Laplant, B.3
|